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To reduce the use of non-specific immunosuppres-
sive drugs detrimental to transplant patient health,
therapies in development aim to achieve antigen-
specific tolerance by promoting antigen-specific reg-
ulatory T cells (Tregs). However, identification of the
natural antigens recognized by Tregs and the contri-
bution of their dominance in transplantation has
been challenging. We identify epitopes derived from
distinctmajor histocompatibility complex (MHC) class
II molecules, sharing a 7-amino acid consensus
sequence positioned in a central mobile section in
complex withMHC class I, recognized by cross-reac-
tiveCD8+Tregs,enriched in thegraft. Antigen-specific
CD8+ Tregs can be induced in vivo with a 16-amino
acid-longpeptide to trigger transplant tolerance.Pep-
tides derived from human HLA class II molecules,
harboring the rat consensus sequence, also activate
and expand humanCD8+ Tregs, suggesting its poten-
tial in human transplantation. Altogether, this work
should facilitate the development of therapies with
peptide epitopes for transplantation and improve our
understanding of CD8+ Treg recognition.
INTRODUCTION
The therapeutic tolerogenic potential of regulatory T cells (Tregs)
has been highlighted by recent studies in numerous fields,
including transplantation, and several clinical trials using poly-
clonal Tregs have started (Fuchs et al., 2018; Tang and Vincenti,
2017). However, it has been shown that antigen-specific Tregs
(both CD4+ and CD8+) have greater potential than unspecific
polyclonal Tregs to control graft rejection and even induce toler-
ance (Flippe et al., 2019; Masteller et al., 2006; Picarda et al.,
2011, 2014; Sagoo et al., 2011; Be´zie et al., 2019). Thus, antigenCell Repor
This is an open access article under the CC BY-Ntherapy appears to be a promising donor-specific therapeutic for
the prevention of transplant rejection, which could diminish or
even replace the non-specific immunosuppressive drugs that
are so deleterious for the patient health in the long term (Marce´n,
2009; Meier-Kriesche et al., 2006; Picarda et al., 2011, 2014).
However, principles for the design and choice of donor-derived
peptides to induce immunoregulation are unknown, and donor-
derived peptides recognized by CD4+ and CD8+ Tregs have
not been identified in human transplantation. So far, donor blood
transfusion protocols in animal models have resulted in highly
efficient donor-specific tolerance induction in a CD8- or CD4-
dependent manner (Douillard et al., 1999; Liu et al., 2004; Ueta
et al., 2018; Vignes et al., 2000), but they are not clinically appli-
cable and could trigger global alloresponses. Using libraries of
donor-derived peptides, we previously identified in a rat model
of tolerance the sequence of a dominant peptide derived from
a donor major histocompatibility complex (MHC) class II
(RT1.Du) molecule and presented by a MHC class I (RT1.Aa)
molecule that specifically triggered activation of CD8+ Tregs
(Picarda et al., 2014). Despite being less studied than CD4+
Tregs (Be´zie et al., 2018a), CD8+ Tregs can efficiently inhibit
transplant rejection in rat models of cardiac transplantation (Be´-
zie et al., 2015a; Guillonneau et al., 2007; Picarda et al., 2017)
and in humanized non-obese diabetic (NOD)-severe combined
immunodeficiency (SCID)-Il2rg/ (NSG) mouse models of hu-
man skin transplantation and xenogeneic graft versus host dis-
ease (GVHD) (Be´zie et al., 2018b). We showed that immune ther-
apy using this peptide alone efficiently inhibited fully
incompatible cardiac allograft rejection in rat through direct in-
duction of T cell receptor (TCR) Vb11 skewed CD8+ Tregs (Pic-
arda et al., 2014). Recently, the structure of a human-induced
CD4+ Treg TCR was solved in complex with a proinsulin-derived
peptide presented by a MHC class II molecule and demon-
strated a 180 polarity reversal, challenging our understanding
of TCR recognition (Beringer et al., 2015).
In this study, we identified and characterized MHC class II-
derived peptides sharing a consensus motif in rat and human,
forming a unique structural complex with MHC class I, andts 29, 4245–4255, December 24, 2019 ª 2019 The Author(s). 4245
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Donor-Derived Bu31 Peptide and
Its Longest Derivatives Activate CD8+ Treg
Function and Crystallize in Complex with
Self-MHC Class I Molecule
CD8+ Tregs were cocultured for 6 days with syn-
geneic CpG-matured pDCs in the presence of
peptides.
(A) Sequence and length of 15 Bu31 derivatives.
Boxes highlight mismatched aa between donor
and recipient.
(B) Treg activation in response to Bu31 derivatives
was analyzed by CD25 expression. Bars represent
the ratio between the percentage of CD25-positive
cells after peptide stimulation and the percentage
of CD25-positive cells in the control condition
without peptide ± SEM. Mann-Whitney test, *p <
0.05, **p < 0.01 versus Bu31 condition. n = 3 to 14
for each peptide.
(C) Structure of the RT1.Aa/Bu31-10 complex.
(D–F) Zoomed-in views of the Bu31-10 peptide,
showing interactions between the RT1.Aa mole-
cule and the P12-Arg (D), P2-Leu (E), and P3-Arg
(F) anchor residues of the peptide, respectively.
Peptide is in green and MHC is in gray; red dashed
lines represent hydrogen bonds formed between
peptide and MHC.activating cross-reactive CD8+ Treg function in vitro and in vivo
upon vaccination, which induced graft tolerance. These findings
improve our understanding of antigen presentation and speci-
ficity to Tregs and could facilitate the development of therapies
with peptide epitopes for transplantation.
RESULTS
A Self-MHC Class I Molecule Accommodates Long
Peptide from a Donor MHC Class II Molecule with a
Mobile Central Section Necessary to Activate CD8+ Treg
Function
We previously described a library of 16 amino acid (aa)-long
overlapping peptides generated from polymorphic domains of
the donor MHC molecules of LEW.1W rats (Picarda et al.,
2014). We showed that peptide 51 (further called Du51,
sequence NREEYARFDSDVGEYR derived from the b1 domain
of the b chain of donor MHC class II RT1.Du) and peptide 31
(further called Bu31, sequence YLRYDSDVGEYRAVTE derived
from the b1 domain of the b chain of donor MHC class II
RT1.Bu) induced highly significant upregulation of CD25 expres-
sion at the cell surface of CD8+CD45RClow Tregs isolated from a
tolerant grafted recipient (treated at day 0 with CD40Ig, a
chimeric molecule blocking the CD40-CD40L pathway) after4246 Cell Reports 29, 4245–4255, December 24, 20196 days of culture in the presence of
matured syngeneic plasmacytoid den-
dritic cells (pDCs) (Picarda et al., 2014)
(Figure S1A). Both peptides shared an 8
aa motif (DSDVGEYR) that is potentially
recognized by CD8+ Tregs.
To determine the sequence of the natu-
ral donor Bu31 peptide recognized byantigen-specific CD8+ Tregs, we designed a library of 9- to 15-
mer degenerated peptides derived from 16-mer Bu31 and 32
peptides (labeled 31-1 to 31-15) (Figure 1A), taking into account
the preferential presence of arginine (R) at the C terminus for
binding to the MHC class I RT1.Aa molecule (Powis et al.,
1996; Stevens et al., 1998a, 1998b; Thorpe et al., 1995). The li-
brary was tested in the same in vitro assay described earlier.
Although none of the 9-mer derivative peptides 31-1 to 31-8 acti-
vated CD8+ Tregs, four longer derivatives—31-10, 31-13, 31-14,
and 31-15—induced strong CD25 upregulation to a similar level
than did Bu31 peptide. Interestingly, they all shared the 7 aa
motif SDVGEYR, also present in the previously described Du51
peptide (sequence NREEYARFDSDVGEYR) (Picarda et al.,
2014).
We refolded the RT1.Aa molecule in complex with 16-mer
Du51 peptide (NREEYARFDSDVGEYR) and Bu31 peptide
(YLRYDSDVGEYRAVTE) and overlapping 12-mer Bu31-10 pep-
tide (YLRYDSDVGEYR) and then assessed the stability of each
complex using a thermal stability assay. We observed markedly
different levels of thermostability among the three peptides: the
highest stability was exhibited by the shorter Bu31-10 peptide,
with a thermal melting (denaturation) temperature of ~62C,
which was ~12C higher than either one of the two 16-mer pep-
tides in complex with RT1.Aa (Table S1). Interestingly, the 12-mer
Bu31-10 peptide shares the same P2-Leu and PU-Arg residues
as 16-mer Bu31 and Du51 peptides, respectively.
Next,wesolved thestructureof theRT1.Aamolecule incomplex
with themost stableBu31-10peptide at a resolutionof 2.9 A˚ (PDB:
6NF7) (Table S2). TheRT1.Aa-Bu31-10 complex crystallized in the
P21 spacegroup,with fivepeptide-MHC (pMHC)complexes in the
asymmetric unit. Each of the five pMHC molecules showed an
overall similar antigen-binding cleft conformation (root-mean-
square deviation [RMSD] of 0.3 A˚). The peptide exhibited a highly
mobile conformation (Figure 1C) in the five complexes (RMSD of
0.5–0.9 A˚), with weak electron density for the central part of the
peptide that was not visible in the electron density (P5-DSDV-
P8) (Figure S1B). Similar to previously solved structures of pep-
tide-RT1.Aa complexes, the RT1.Aa-Bu31-10 complex showed a
preferred small hydrophobic residue at P2 (Leu/Pro), a larger
half-buried P3 residue (Arg/Phe), and a PU-Arg (Rudolph et al.,
2002; Speir et al., 2001). The two anchor residues at P2 and PU
are shared with the less stable 16-mer Du51 and Bu31 peptides.
The PU-Arg of Bu31-10 peptide forms a salt bridge with Asp116,
Glu97, and Asp77 of the F pocket within the antigen-binding cleft
(Figure 1D). Meanwhile, Bu31 peptide has a PU-Glu that is unfa-
vorable in the negatively charged F pocket of RT1.Aa, which may
explain the decreased stability of Bu31 peptide compared with
Bu31-10 peptide (Table S1). The P2-Leu of Bu31-10 peptide sits
above Tyr7 and Met45 of RT1.Aa (Figure 1E); a larger residue
such as the P2-Arg of Du51 peptide might lead to steric clashes
within the B pocket of the RT1.Aa, which would be unfavorable.
This might explain the lower stability of Du51 peptide compared
with Bu31-10 peptide. Finally, the P3-Arg of Bu31-10 peptide,
which is also shared with Bu31 peptide, formed a salt bridge
with Glu97 and a hydrogen bond with Tyr152, further stabilizing
the peptide within the RT1.Aa molecule (Figure 1F). Collectively,
our data show that the higher stability of Bu31-10 peptide results
from favored anchor residues at positions P2, P3, and PU that
were partially missing within Bu31 or Du51 peptides. In addition,
the structure of Bu31-10 peptide in complex with RT1.Aa reveals
a mobile central section of the peptide that might be stabilized
upon TCR ligation and thus confirms the importance of the
consensus sequence SDVGEYR present in each peptide.
A Cross-Reactive CD8+ Treg Population Recognizes
Peptides Derived from Different MHC Molecules
To further understand the role of this consensus sequence in the
mobile section, we generated MHC class I tetramers for RT1.Aa/
Bu31-10 (tet Bu31-10) and RT1.Aa/Du51 (tet Du51) and tested
specific binding of CD8+CD45RClow Tregs from spleen, graft,
and blood of cardiac graft recipients who had been tolerant for
>120 days. Both PE- and APC-conjugated tet Bu31-10 or tet
Du51 were used to discriminate a true signal from noise as
described previously (Picarda et al., 2014). Non-specific binding
to a BV421-labeled RT1.Aa/MTF-E (Tet MTF-E) control tetramer
was eliminated, together with dead cells (Figure 2A). Around
1.38% of CD8+CD45RClow Tregs in the graft, 0.67% in the
spleen, and 0.25% in the blood were specific for Bu31-10 pep-
tide (Figures 2A, left panels, and 2B). This percentage is 3- to
5-fold lower than the one of dominant Du51-specific cells (Fig-
ures 2A, middle panels, and 2B) (Picarda et al., 2014). Analysis
of potential Treg cross-reactivity showed that all Bu31-10-spe-cific Tregs also cross-recognized peptide Du51 but a fraction
of Du51-specific Tregs did not bind to tet Bu31-10 (Figures 2A,
right panels, and 2B). Cross-reactive Tregs were mostly present
in the graft, followed by the spleen and to a lesser extent the
blood. Moreover, we showed that 20% to 40% of Du51 and
Bu31-10 antigen-specific Tregs express FoxP3 (Figure 2C).
Given the non-canonical length of the peptide and the pres-
ence of the consensus sequence recognized by both Du51
and Bu31-10 antigen-specific Tregs, we next performed alanine
scanning mutagenesis of the Du51 dominant peptide to deter-
mine the contribution of each residue to CD8+ Treg recognition
and activation (Figure 2D). All alanine analogs showed a substan-
tial reduction in Treg activation compared with wild-type pep-
tide. Substitution of P16-Arg (R16A) resulted in the most
significant loss of activation, which might result from its critical
role in peptide stability. Substitutions at positions P3-Glu, P4-
Glu, and P7-Arg and within the DSDVG peptide motif at P10-
Ser and P12-Val also significantly reduced Treg activation,
possibly because of peptide instability and defective TCR liga-
tion as suggested by Bu31-10 structural analysis.
Altogether, these results demonstrated that a fraction of
CD8+CD45RClow Tregs harbored a flexible TCR capable of
recognizing at least two distinct peptides but with a consensus
sequence probably key to the recognition.
Stimulation with Bu31 Peptide Leads to Efficient
CD8+CD45RClow Treg Activation and Suppressive
Function
Given the low frequency of Bu31-specific cells within the total
CD8+CD45RClow Treg population, we assessed the capacity of
Bu31 peptide to stimulate and increase Treg function after
6 days of incubation with syngeneic pDCs (Figure 2E). Bu31-stim-
ulatedCD8+Tregsupregulated their secretionof interferongamma
(IFNg), an important cytokine for CD8+ Treg function (Guillonneau
etal., 2007),asmeasured in theculture supernatant (Figure2E)and
their expression of CD25 and CD71 asmeasured by flow cytome-
try (Figures 2F and S1A). We also observed a trend for an increase
in CD28 and MHC class II expression, but no change in Foxp3
level. After 6 days of Bu31 or control peptide stimulation through
the indirect pathway of recognition, CD8+CD45RClow Tregs were
recoveredand tested for their suppressive capacity in a secondary
coculture of effector CD4+CD25 T cells stimulated by the direct
allorecognition pathway with donor pDCs as previously described
(Picarda et al., 2014). In this assay, suppression depends on the
efficacy of Treg pre-stimulation with peptide and relies on
bystander suppression through secretion of inhibitory factors.
Bu31-stimulated Tregs significantly suppressed effector T cells
proliferation compared with Tregs cultured with a non-activating
peptide (Figure 2G). Altogether, we showed Bu31 peptide effi-
ciently activated CD8+CD45RClow Tregs and potentiated their
suppressive activity in vitro.
In Vivo Tolerogenic Bu31 Peptide Vaccination Induces
Tolerance to a Fully Mismatched Cardiac Graft in Rat
through CD8+CD45RClow Tregs
To assess the potential of Bu31 peptide in in vivo generation of
CD8+CD45RClow Tregs and in allograft survival, animals were
treated with the peptide as monotherapy at doses of 0.5 orCell Reports 29, 4245–4255, December 24, 2019 4247
(legend on next page)
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1 mg/day for 28 days, starting day 7 before transplantation and
constantly released intraperitoneally (i.p.) by mini-osmotic
pumps (Figure 3A). Although a dose of 0.5 mg/day was not suf-
ficient to delay cardiac graft rejection, a higher dose of 1 mg/day
of peptide induced indefinite allograft survival in 80% of recipi-
ents (**p < 0.01 compared with 0.5 mg/day and no treatment)
(Figure 3B). Long-survival graft induction was donor specific,
because third-party Brown Norway (BN) grafts of a different
haplotype (RT1n) that did not contain the conserved motif were
quickly rejected. In addition, tolerance induced by peptide vacci-
nation depended on CD8+ T cells, because recipients depleted
of CD8+ cells using a depleting anti-CD8 monoclonal antibody
(mAb) (OX8 clone) (Be´zie et al., 2015b; Guillonneau et al., 2007)
also rapidly rejected their graft. Histologic analysis of the cardiac
graft at day 120 following transplantation showed no signs of
chronic rejection (Figure 3C) according to a score previously
established (Be´zie et al., 2015a; Guillonneau et al., 2007; Picarda
et al., 2017). Furthermore, anti-donor humoral responses
were abrogated in long-term Bu31-treated recipients (Fig-
ure 3D). Finally, we analyzed the suppressive capacity of
CD8+CD45RClow Tregs from long-surviving tolerant recipients
in vitro in the presence of effector CD4+CD25 T cells and donor
pDCs (Figure 3E) and in vivo upon adoptive transfer in newly
grafted irradiated recipients (Figure 3F). Tregs fromBu31-treated
recipients were significantly more suppressive than naive cells
(Figure 3E), with an almost total inhibition of effector CD4+
T cell proliferation at 1:4 and 1:2 effector:suppressor ratios.
In vivo, adoptive cell transfer of either total splenocytes or
CD8+CD45RClow Tregs from long-term tolerant Bu31-treated
rats significantly delayed allograft rejection in secondary trans-
planted recipients compared with naive splenocytes (Figure 3F).
Overall, these results demonstrated that short-term tolerogenic
vaccination starting before transplantation efficiently induced
tolerance, inhibited cellular and antibody-mediated rejection,
and improved CD8+CD45RClow Treg suppressive function.
16 aaHumanMHCClass II-Derived Peptides Bearing the
Conserved SDVGE-X-R Motif Activate Human
CD8+CD45RClow Tregs
Tobetter understand the relevanceof our findings in human trans-
plantation, wedesigned four 16 aa peptides from four randomhu-Figure 2. A Cross-Reactive CD8+ Treg Population Recognizes Distinct
Necessary for Activation and Efficient Suppressive Function
(A and B) More than 120 days after cardiac transplantation and CD40Ig treatme
dependent experiments on graft, spleen, and blood from tolerant recipients. Perc
E (irrelevant tetramer), and CD8+CD45RClow cells. One representative staining
(C) Percentage of Foxp3+ cells among Bu31-10+, Du51+, and Bu31-10/Du51 d
represent mean ± SEM.
(D) Treg activation induced by native Du51 and a panel of single amino acid alani
after 6 days of coculture with syngeneic CpG-matured pDCs. Bars represent the
*p < 0.05 versus Du51, n = 6 for each peptide.
(E and F) Fresh CD8+ Tregs and syngeneic CpG-matured pDCs were cultured
indicatedmarkers was analyzed in the culture supernatant by ELISA (E) or on CD8
SEM. Mann-Whitney test, *p < 0.05, **p < 0.01, n = 4 to 7.
(G) At day 6, Tregs were isolated by cell sorting (TCR+), and their capacity to sup
dividing LEW.1ACD4+CD25 T cells after stimulation with donor LEW.1WpDCsw
stimulated CD8+ Tregs at a 1:1 ratio of effector:suppressor. On the left, the graph
****p < 0.0001. On the right, representative histograms are shown.man histocompatibily leucocyte antigen (HLA) class II alleles
based on their alignment with sequences of the rat Du51 peptide
(NREEYARFDSDVGEYR) and the overlapping 12-mer Bu31-10
peptide (YLRYDSDVGEYR), both bearing the SDVGEYR motif at
the C-terminal end (Figure 4A). We individually tested these hu-
man peptides differing at position 2, 5, 6, 14, or 15 in a 5-day cul-
ture assay using CD8+CD45RClow Tregs and autologous pDCs
from the same individuals in the presence of interleukin (IL)-2
and CpG in serum-free Texmacs medium (Figure 4A). CD25 and
CD69 expression was upregulated on Tregs following incubation
with Hpep1, Hpep2, and Hpep4 peptides and reached statistical
significance forHpep2 (Figure4B). These threepeptides share the
conserved SDVGE-X-R 7 aamotif; Hpep3 has a valine (V) in place
of the glutamic acid (E) at p14 of the peptide, probably affecting
TCR recognition. To determinewhether Tregs could be expanded
using such HLA class II-derived peptide, we set up an expansion
protocol using sorted CD8+ Tregs and APCs from the same indi-
vidual with the Hpep2 peptide in the presence of IL-2, IL-15, and
CpG and compared the results with those of a polyclonal stimula-
tion (anti-CD3/CD28 mAbs) (Be´zie et al., 2018b) (Figure 4C).
Hpep2stimulation resulted in8-foldexpansionof totalCD8+Tregs
in 14days, although actual expansionof the small Hpep2-specific
Treg fraction present at day 0 may be much higher (Figure 4D).
Importantly, both Hpep2- and anti-CD3/CD28 mAb-stimulated
Tregs retained their capacity to suppress an allogeneic immune
response after expansion, similar to fresh CD8+ Tregs (Figure 4E).
Peptide-stimulated Tregs tend to be more suppressive than
polyclonal Tregs, suggesting the potential benefit of expanding
antigen-specific Tregs for therapy.We did not observe significant
differences in the level of expression of Foxp3, GITR, IL-10, IFNg,
and IL-34 in Hpep2 or anti-CD3/28 expanded CD8+ Tregs
(Figure S2).
Altogether, HLA class II-derived peptides bearing the
consensus SDVGE-X-R 7 aa motif efficiently activated and
expanded suppressive human CD8+CD45RClow Tregs.
DISCUSSION
Understanding antigen presentation, recognition, and subse-
quent Treg activation and expansion is crucial for the develop-
ment of therapeutic strategies for the treatment of numerousDonor Peptides Sharing a Consensus Sequence with Key Residues
nt, dual Tet Bu31-10 and Tet Du51 staining was performed ex vivo in five in-
entages of tetramer+ cells are shown after gating on live cells (DAPI), Tet MTF-
(A) and mean ± SEM (B) are shown.
ouble-positive CD8+CD45RClow Tregs from graft, spleen, and blood. Graphs
ne analogs (indicated as N1A to R16A for each position in the Du51 sequence)
fold change of CD25 activation compared with Du51 dominant peptide ± SEM.
for 6 days, alone, with a control peptide or with Bu31 peptide. Expression of
+ Tregs by flow cytometry (F) after in vitro stimulation. Graphs represent mean ±
press MLR assay was analyzed. The relative proportion of naive CFSE-labeled
as analyzed at day 6 of culture, in the absence or presence of 6 days of peptide-
represents mean ± SEM. n = 4. One sample t test versus 100% proliferation,
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Figure 3. Tolerogenic Vaccination with Bu31 Peptide Induces Allograft Tolerance through Potentiation of Specific CD8+ Tregs’ Suppressive
Activity
(A) Tolerogenic vaccination protocol with mini-osmotic pump implantation in the abdomen of cardiac allograft recipient from day 7 before transplantation to
day 21 post transplantation.
(B) Recipients were either untreated (n = 9) or treated with short-term continuous peptide infusion by i.p. mini-osmotic pumps delivering either 0.5 mg/day (n = 6)
or 1mg/day (n = 5) of Bu31 peptide alone or combinedwith a depleting anti-CD8amAb (OX8) (n = 2) or 1mg/day in the BN/LEW.1A strain combination (n = 4). Log
rank test, *p < 0.05, **p < 0.01.
(C) Representative H&E histology of two representative sections of cardiac graft from long-surviving Bu31-treated rats at day 120 post-transplantation and
treatment. Arrows indicate the intimal wall of the vessels. Original magnification, 3100.
(legend continued on next page)
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diseases, such as transplant rejection and auto-immunity. We
previously demonstrated that a 16-mer-long dominant peptide
derived from a donor MHC class II molecule strongly activated
CD8+ Tregs (Picarda et al., 2014), contrasting with literature
describing a more common short length preference for MHC
class I. In the present study, we made a similar observation
with a peptide derived from a different MHC class II molecule
(16 aa original sequence and not less than a derivative of
12 aa). Historically, studies of random peptide libraries and of
mass spectrometry have been limited to short lengths of 8 to
10 aa and have allowed the development of powerful tools for
prediction of potential antigenic epitopes but rarely exceeded
11 aa. However, about 10% of presented peptides have a length
greater than 11 aa (Burrows et al., 2006), even up to 25 aa (Bell
et al., 2009). Recent studies suggest that MHC class I can
accommodate peptides much longer than previously estab-
lished, inviting broadening studies and peptide binding algo-
rithms up to 15/16 aa. This clear preference for long peptides
from two distinct MHC molecules observed for CD8+ Tregs is
intriguing, and it would be interesting to know whether this is a
general feature of CD8+ Tregs. Rist and colleagues demon-
strated that HLA polymorphism affects the length of peptide pre-
sentation and CD8+ T cell response (Rist et al., 2013). It is not
clear yet whether our finding regarding the characteristic of
structural presentation is restricted to RT1.Aa MHC class I pre-
sentation, known to accommodate long peptides (Stevens
et al., 1998b), or whether it applies to other haplotypes in rat
and human, as suggested by our results using long peptides
in the human setting. Binding of long peptides on MHC class I
has been shown in the same rat strain for a minor antigen pep-
tide of 13 aa called MTF-E, and the structure revealed two con-
formations of the peptide, which forms a large and flexible bulge
out of the MHC cleft (Speir et al., 2001), suggesting a high level
of peptide flexibility that can be observed for long peptides in
complex with MHC class I molecules (Chan et al., 2018; Ebert
et al., 2009; Hassan et al., 2015; Josephs et al., 2017). Peptide
length, and perhaps flexibility, might be important for CD8+ Treg
recognition, because no peptide variant shorter than 15 aa for
the RT1.Du and 12 aa for the RT1.Bu chains could efficiently
activate CD8+ Tregs. In addition, usage of different anchor res-
idues for the three peptides analyzed seems greater than what
has been commonly described for T cell epitopes (Powis et al.,
1996; Stevens et al., 1998a; Thorpe et al., 1995). In a tumor
model, two distinct polyclonal TCRs recognizing a HLA class
I-restricted dominant tumor epitope adopted differing TCR
recognition modes, suggesting that extensive flexibility at the
TCR-pMHC class I interface engenders recognition (Chan
et al., 2018). An interesting feature of the different peptides(D) Immunoglobulin G (IgG), IgG1, IgG2a, or IgG2b alloantibody production in na
transplantation. Graphs represent MFI ± SEM. Two-way ANOVA test, Bonferron
(E) In vitro CD8+ Treg suppressive activity from naive or Bu31-treated cardiac al
(n = 5) or Bu31-CD8+ (n = 3) Tregs, CFSE-labeled CD4+CD25 effector T cells,
T cells in the control condition with pDCs and without Tregs (~80%) was given the
the relative proportion of dividing CD4+ T cells. Two-way ANOVA test, Bonferroni p
effector:suppressor is shown.
(F) 120 after transplantation, 1503106 total splenocytes or 2.53106 sorted CD8+
adoptively transferred into naive irradiated LEW.1A recipients transplanted with
survival as monitored by palpation. Log rank test, *p < 0.05, **p < 0.01.we studied was the presence of a common motif DSDVGEYR,
allowing recognition by a common pool of cross-reactive Tregs.
Tetramer staining revealed that Bu31-10-specific CD8+ Tregs
also recognized the Du51 peptide, suggesting either flexibility
of the TCR recognition or focused recognition on the shared
peptide motif. We previously showed that Du51-specific Tregs’
TCR was biased toward the Vb11 family, suggesting that this
may also be the case for Bu31-specific Tregs (Guillonneau
et al., 2007; Picarda et al., 2014). We confirmed that the two al-
lopeptides involved in acute rejection in the same mismatched
cardiac allograft model did not activate CD8+ Tregs and that
effector T cells isolated from rejecting untreated animals did
not recognized the tolerogenic peptides (Ballet et al., 2009; Pic-
arda et al., 2014).
The use of a soluble peptide as a therapeutic to decrease
transplant rejection and selectively induce tolerance through
antigen-specific Tregs was both feasible and efficient in our
model. Although these Tregs were capable of potent bystander
suppression in vitro, they did not prevent third-party allograft
rejection in vivo, possibly because of a lower Treg:Teff ratio
in vivo, stronger alloresponse to the third-party antigens, and
the role played by innate immunity and B cells in rejection.
Future work is needed to assess the detailed mechanism of
tolerance induction in vivo and better understand the potential
of bystander suppression mediated by antigen-specific Tregs
and the roles played by IFNg, transforming growth factor b
(TGF-b), and IL-34. Although others have shown pMHC multi-
mers can efficiently inhibit autoimmune diseases (Masteller
et al., 2003), administration of tolerogenic pMHC multimers
induced Treg apoptosis and graft rejection in our model (data
not shown), suggesting a high avidity of the TCR for these tol-
erogenic multimers resulting in strong activation-induced cell
death and the requirement for low-antigen doses in the context
of transplantation (Mallone et al., 2004; Oling et al., 2010).
Several studies have demonstrated the immunomodulatory ef-
fect of synthetic peptides derived from conserved regions of
MHC molecules on alloimmune responses (Zang and Murphy,
2005): in vitro by inhibition of cell-cycle progression (Boytim
et al., 1998) or induction of apoptosis (Murphy et al., 1999)
and in vivo by inhibiting activation and effector function of allo-
geneic T cells in a mouse model of donor-specific transfusion
(Murphy et al., 2003). In addition, administration of a peptide
derived from the HLA-B7 molecule named Allotrap and associ-
ated with cyclosporine prolonged skin allograft survival in mice
(Buelow et al., 1995) and heart allograft survival in rats while
attenuating arteriosclerosis (Murphy et al., 1997). In mice, intra-
tracheal administration of a 15-mer derived from the hypervari-
able region of H2-Kb prolonged cardiac allograft survivalive (n = 3), untreated (n = 3), or Bu31-treated (n = 4) animals > 120 days after
i post-test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
lograft recipients following cell sorting > 120 days after transplantation. Naive
and allogeneic pDCs were cocultured for 6 days. Proliferation of CD4+CD25
value 100 in each experiment. On the left, the graph represent mean ± SEM of
ost-test, ****p < 0.0001. On the right, one representative staining at ratio 1:1 for
Tregs from the spleen of naive or Bu31-treated cardiac allograft recipients were
LEW.1W donor heart. Results are expressed as the percentage of allograft
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Figure 4. Long MHC Class II Peptides Activate and Expand Human CD8+ Tregs
(A) 16 aa peptides were designed on 4 human MHC class II alleles and tested for CD8+ Treg activation in 5 days of culture with HLA-A2+ syngeneic pDCs in
medium supplemented with CpG and IL-2. Peptide mismatches are highlighted in red.
(B) CD8+ Treg activation in response to each peptide was quantified based on CD25 and CD69 expression. Bars ± SEM represent the fold change of positive cells
after peptide stimulation compared with the control condition with an irrelevant peptide. Wilcoxon test versus 1, *p < 0.05. n = 9 to 14 for each peptide.
Representative histograms are shown on the right.
(C) Protocol of CD8+ Treg expansion by Hpep2 peptide. CD8 Tregs were stimulated at day 0 and day 7 by syngeneic HLA-A2+ APCs, Hpep2 peptide, IL-2, IL-15,
and CpG. Cytokines were added twice a week.
(D) Total Treg fold expansion after 14 days of culture with Hpep2 or anti-CD3/anti-CD28 mAbs (versus day 0). Individual samples and mean ± SEM are shown.
(E) After 14 days of peptide or polyclonal stimulation, expanded Tregs were tested for suppressive activity on syngeneic CFSE-labeled CD4+CD25 T cells
stimulated with allogeneic APCs pooled from 3 healthy volunteers, compared with fresh Tregs. Bars ± SEM represent the relative proportion of dividing
CD4+CD25 T cells. ***p < 0.001. n = 2 to 5. Representative histograms are shown on the right.(Akiyama et al., 2002) or induced tolerance, in combination with
a non-depleting anti-human CD4 antibody (Aramaki et al.,
2003), and generated regulatory cells. Finally, according to a pi-
lot study in humans, oral administration of low doses of pep-
tides derived from donor MHC (HLA-DR2) molecules to patients
with chronic dysfunction of renal allograft induced complete in-
hibition of indirect alloreactivity in vitro, but suppression mech-
anisms have not been elucidated (Womer et al., 2008). Du51
and Bu31 peptides identified in our model have >90% homol-4252 Cell Reports 29, 4245–4255, December 24, 2019ogy with human HLA-DP, HLA-DQ, and HLA-DR molecules.
To emphasize the clinical scope and potential future therapeutic
interest of our work, we studied the response of human CD8+
Tregs to these homologous peptides (Be´zie et al., 2018b).
One peptide in particular bearing the consensus SDVGE-X-R
7 aa motif efficiently activated and expanded CD8+ Tregs.
Importantly, Tregs retained their suppressive potential and tol-
erogenic phenotype after 14 days of expansion, suggesting
this peptide specifically expanded Tregs, not effector T cells.
However, expansion remained low compared to polyclonal anti-
CD3/CD28 mAb stimulation, although suppressive potential
seems to be slightly increased, and future work is needed to
optimize growing conditions and obtain sufficient CD8+ Treg
numbers for cell therapy.
Altogether, this work improves our understanding of CD8+
Treg recognition and sets the path for development of therapies
with peptide epitopes in transplantation.STAR+METHODS
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Mouse TGFb1-PECF594 BD Biosciences Cat#562422; TW4-9E7; RRID: AB_2737614
Mouse IFNg-PECF594 BD Biosciences Cat#562392; B27; RRID: AB_11153859
Fixable Viability Dye eF506 ThermoFisher Scientific Cat#65-0866
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
F Block BD Biosciences Cat#564220
RT1.Aa/Du51 tetramer This paper N/A
RT1.Aa/Bu31-10 tetramer This paper N/A
RT1.Aa/MTF-E tetramer This paper N/A
Streptavidin-PE Thermofisher Scientific Cat#S21388
Streptavidin-APC Thermofisher Scientific Cat#S32362
Streptavidin-BV421 Biolegend Cat#405225
Rat FoxP3-Pacific Blue eBiosciences Cat#48-5773-82; FJK-16 s; RRID: AB_494151
Mouse anti-CD28 BD Biosciences Cat#555726; CD28.2; RRID: AB_396069
Mouse anti-CD3 European Collection of Authenticated Cell Culture OKT3; RRID:CVCL_2665
Mouse anti-CD3-PE BD Biosciences Cat#555340; RRID: AB_395746; clone HIT3a
Bacterial and Virus Strains
BL21 E. Coli ATCC N/A
AdCD40Ig Plateforme de Production de vecteurs viraux,
IRS, Nantes
N/A
Chemicals, Peptides, and Recombinant Proteins
Penicillin Streptomycin GIBCO Cat#15140-122
rhIL-2 Proleukin, Novartis N/A
rhIL-15 Miltenyi Biotec Cat#103-095-765
Custom peptides GL Biochem Ltd (China) N/A
Collagenase D Sigma Aldrich Cat#1108882001
Guanidine Rowe CG0112
Urea Sigma Aldrich U1250-1KG
Tri-HCL Goldbio T-400-5
Na-EDTA Sigma Aldrich E4884-500G
L-arginine-HCL Sigma Aldrich A5131-1KG
Oxidized gluthatione Sigma Aldrich G4376-10G
Reduced gluthatione Goldbio G-155-500
Bis-Tris-Propane Sigma Aldrich B6755-25G
PEG 8000 Sigma Aldrich 202452-500G
Mg2SO4 Sigma Aldrich M7506-500G
Critical Commercial Assays
Fix/Perm kit Ebiosciences Cat#00-5223-56
IFNg ELISA OptEIA BD Biosciences Cat#558861
IL-10 ELISA OptEIA BD Biosciences Cat#555134
IL-12 ELISA ThermoFisher Scientific Cat#KRC2371
TGFb ELISA R&D System Cat#MB100B
Deposited Data
Crystal structure RT1.Aa/Bu31-10 This paper PDB: 6NF7
Experimental Models: Cell Lines
Blood PBMCs Etablissement Francais du Sang N/A
Experimental Models: Organisms/Strains
Rat: LEW.1A Janvier Labs N/A
Rat: LEW.1W Janvier Labs N/A
Rat: Brown-Norway Charles River N/A
CpG 2006 Eurofins Genomics PTO
CpG ODN 1826 Eurofins Genomics PTO
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pET30 vector Genscript N/A
Software and Algorithms
XDS Kabsch, 2010 http://xds.mpimf-heidelberg.mpg.de/;
RRID: SCR_015652
AIMLESS Evans and Murshudov, 2013 http://www.ccp4.ac.uk/html/aimless.html;
RRID: SCR_015747
Phaser program Read, 2001 http://www.phaser.com/; RRID: SCR_014219
Coot software Emsley et al., 2010 http://bernhardcl.github.io/coot/; RRID: SCR_014222
Buster program Smart et al., 2012 https://www.globalphasing.com/buster/;
RRID: SCR_015653
Pymol Schro¨dinger https://pymol.org/2/; RRID: SCR_000305
FlowJo X FlowJo LLC https://www.flowjo.com/; RRID: SCR_008520
GraphPad Prism 7 GraphPad https://www.graphpad.com/scientific-
software/prism/; RRID: SCR_002798
Other
PMA Sigma Aldrich Cat#P8139
Ionomycin Sigma Aldrich Cat#C9272
Brefeldin A Sigma Aldrich Cat#B6542
CFSE Invitrogen Cat#34554
Ficoll-Paque Eurobio Cat#CMSMSL01-01
Mini osmotic pump Alzet Cat#2002
Magnetic beads Dynabeads, Invitrogen Cat#11033LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents may be directed to, andwill be fulfilled by the corresponding author Carole Guillonneau
(carole.guillonneau@univ-nantes.fr).
Tetramers generated in this study will be made available on request but we may require a payment and a completed Materials
Transfer Agreement if there is potential for commercial application.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and cardiac transplantation models
Congenic fully MHC-incompatible LEW.1W (RT1u as donors) and LEW.1A (RT1a as recipients) male rats of 8-12 weeks old were used
to perform heterotopic heart allotransplantations as previously described (Guillonneau et al., 2007; Guillot et al., 2002). BN (RT1n) rats
were used as 3rd party donors. Allograft long term survival was induced by injection at 3 points into the cardiac ventricular walls of
2.1010 infectious particles of adenovirus encoding for extracellular portion of mouse CD40 fused to constant domains of human IgG1
(AdCD40Ig) (Guillonneau et al., 2007; Guillot et al., 2002).
All animal studies were approved by the Pays de la Loire regional French ethics committee for animal care and use.
Human Samples
Blood was collected at the Etablissement Franc¸ais du Sang (Nantes, France). Heparinized blood samples were taken from healthy
volunteers after signing an informed consent approved by the ethical committee of relevant institutions (#NCPDL-PLER-2018 180).
The gender of the donors was not available.
METHOD DETAILS
Peptides libraries
Rat
9 to 15-mer degenerated peptides with aa lagging designed to cover the sequence of parental 16-aa peptides selected and 16-aa
peptides with point scan alanine mutations were synthesized by GL Biochem Ltd (China). All aa sequences were confirmed and alle3 Cell Reports 29, 4245–4255.e1–e6, December 24, 2019
peptides were > 95% homogeneous by analytical reverse phase HPLC. The lyophilized peptides were dissolved in 0.4% sterile
DMSO in sterile water and stored at 80C. Peptides were diluted in complete RMPI-1640 at a concentration of 120mg/ml.
Human
16-aa peptides were randomly designed on human MHC-II alleles based on their alignment with rat sequence (Genscript, USA). Pu-
rity was > 90%. Human peptides were dissolved and stored as described above and diluted at 120mg/ml in Texmacsmedium for use
in vitro.
Cell purification
Rat
pDCs, CD8+CD45RClow T cells and CD4+CD25- T cells were purified as previously described (Picarda et al., 2014). Briefly, T cells
recovered from spleen following red blood cell lysis were first enriched by negative selection using a mixture of anti-gd T cell (V65
clone), anti-CD45RA B cell (OX33 clone), anti-CD161 NK cell (3.2.3 clone) and anti-CD11b/c monocyte (OX42 clone) mAbs andmag-
netic beads (Dynal, Invitrogen). Enriched T cells were then labeled with anti-CD45RC-biotin (OX22 clone) and Strepavidin-PE-Cy7,
anti-CD8a–PE (OX8 clone), and for CD4+CD25- T cells by adding anti-TCRab-Alexa 647 (R73 clone), anti-CD25-FITC (OX39 clone)
mAbs and flow-sorted with FACSAria (BD Biosciences). Purity was greater than 98%. For pDCs, splenocytes were digested with
collagenase D and enriched for pDCs by negative selection using a mixture of anti-TCR (R73 and V65 clones) T cell, anti-CD45RA
(OX33 clone) B cell mAbs and magnetic beads. Enriched cells were then labeled with anti-CD45R-PE (His24 clone), anti-CD4-
APC (OX35 clone), anti-TCR-FITC (R73 clone) and anti-CD45RA-FITC (OX33 clone). pDCs were sorted after gating on FITC negative
cells, CD45R and CD4 positive cells. Antibodies were obtained from the European Collection of Cell Culture (Salisbury, UK).
Human
PBMCs were isolated by Ficoll-Paque density-gradient centrifugation at 2000 rpm for 20 min at room temperature without brake.
Remaining red blood cells and platelets were removed using 5 min incubation with a hypotonic solution and centrifugation at
1000 rpm for 10 min at 4C. For pDC and T cell sorting, B cells, monocytes and NK cells were magnetically depleted (Dynabeads,
Invitrogen) by using anti-CD19 (clone: HBI19, eBiociences), anti-CD14 (clone: M5E2, eBiociences) and anti-CD16 (Clone: 3G8, pu-
rified) mAbs respectively. Enriched PBMCs were stained with anti-CD45RC-FITC (clone: MT2, IQ-Products), anti-CD8a-PE-Cy7
(clone: RPT8, eBiociences) and anti-Nrp1-PE (clone: u21-1283, BD Biosciences) for sorting of CD8a+CD45RClow Tregs and Neuro-
philin-1+ pDCs. Enriched PBMCs were stained with anti-CD3-PeCy7 (clone SK7, BD Biosciences), anti-CD4-PerCP-Cy5.5 (clone:
RPA-T4, BD Biosciences) and anti-CD25- APC-Cy7 (clone: M-A251, BD Biosciences) mAbs for sorting of CD4+CD25- Teff cells.
APCs were obtained from PBMCs by either magnetically depleting T cells with an anti-CD3 (OKT3 purified, 5mg/ml) mAb (for stim-
ulation of Teff in proliferation assays) or by gating out T cells during sorting using anti-CD3-PE (clone: HIT3a, BD Biosciences) (for
activation and expansion tests). FACS ARIA II (BD biosciences, Mountain View, CA) was used for sorting. Purity was greater
than 98%.
Peptide stimulation assay
Rat
1.25 3 104 pDCs from naive LEW.1A rats, 5 3 104 CD8+CD45RClow Tregs from tolerant > 120 days CD40Ig-treated recipients and
120 mg/ml of individual allogeneic peptideswere plated in triplicate in RPMI-1640medium supplementedwith 10%FCS and 0.5mMof
CpGODN 1826 in round-bottom 96 wells plates for 6 days at 37C, 5%CO2. The CD25 activation marker was then analyzed by flow
cytometry.
Human
CD8+CD45RClow Treg cells and autologous pDCs from the same healthy HLA-A2+ donor were co-cultured in serum-free Texmacs
medium (Miltenyi Biotec) supplemented with IL-2 (25 U/ml, Proleukin, Novartis), CpG ODN 2006 (0.5 mM) and the different synthe-
sized peptides (120 mg/ml) at a ratio 4:1 of Tregs:pDCs for 5 days. CD8+CD45RClow Treg activation was analyzed based on expres-
sion of CD69 and CD25 markers. As negative control and in order to normalize the results, an irrelevant peptide was used (ALIAPV-
HAV). Dapi was used as viability marker. As a positive control, CD8+CD45RClow Tregs were stimulated with anti-CD3 (OKT3, 1 mg/ml)
and anti-CD28mAbs (clone: CD28.2; 1mg/ml). Results were analyzed using the FACSCanto II cytometer (BDBiosciences) and Flowjo
software (Tree Star, Inc. USA, version 10).
Suppression assays
Rat
53 104 CFSE-labeled CD4+CD25- T cells from naive LEW.1A rats and 1.253 104 allogeneic pDCs from naive donor LEW.1Wanimals
were plated in triplicate for 6 days in supplemented RPMI-1640 medium in round-bottom 96 wells plates in presence of 53 104 facs-
sorted CD8+CD45RClow Tregs from tolerant > 120 days CD40Ig-treated recipients (previously expanded for 6 days with one peptide
in presence of pDCs from a naive LEW.1A rats) or from tolerant > 120 days Bu31-treated recipients, or from non-grafted non-treated
naive rats.
Proliferation of CFSE-labeled CD4+CD25- T cells was analyzed by flow cytometry on FACS Canto II cytometer (BD Biosciences)
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Human
CFSE-labeled CD4+CD25- Teffs and CD8+CD45RClow Tregs from the same healthy volunteer (HLA-A2+) were co-cultured with a pool
of allogeneic APCs from 3 different healthy donors (HLA-A2-) in RPMI1640 medium supplemented with 5% AB serum. Culture was
done at 1:1:1 ratio (where 1 = 5x104 cells/well) for 5 days in triplicate in a V-bottom 96 well plate. Proliferation of CD4+CD25-
responder T cells was analyzed by flow cytometry (FACS Canto II BD Biosciences TM) by gating on CD3+CD4+ living cells (DAPI
negative) and using Flowjo software (Tree Star, Inc. USA, version 10).
Extracellular and intracellular stainings
Rat
For extracellular staining, cells were stained with anti-TCRab (R73, Alexa Fluor 647–conjugated), anti-CD8a (OX8, PE-Cy7-conju-
gated, Ebiosciences), anti-CD4 (W3.25, PE-Cy7-conjugated), anti-CD45RC (OX22, FITC-conjugated), anti-CD28 (JJ319, biotin- con-
jugated), anti-CD71 (OX26, biotin- conjugated), anti-CD25 (OX39, biotin-conjugated) and anti-MHC-II (OX6, biotin-conjugated)
mAbs. For intracellular staining, cells were permeabilized and stained for Foxp3 (biotin- conjugated, Ebiosciences) using the BD cy-
tofix/cytoperm kit (BD Biosciences) according to the manufacturer’s instructions. All biotinylated mAbs were visualized using Strep-
tavidin-PerCP.Cy5.5 (BDBiosciences). Cells were gated by their morphology, DAPI negative viable cells were selected, fluorescence
was measured on a FACS Canto II cytometer (BD Biosciences) and data were analyzed using FlowJo software (Tree Star, Inc. USA,
version 10).
Human
For the analysis of GITR (clone: DT5D3, Miltenyi Biotec), Foxp3 (clone:259D/C7, BD Biosciences), IL-10 (clone: JES3-9D7, BD Bio-
sciences), IL-34 (clone: IC5265P, R&D), TGFb1 (clone: TW4-9E7, BD Biosciences) and IFNg (clone: B27, BD Biosciences),
CD8+CD45RClow Treg cells were stimulated with PMA (50 ng/ml) and ionomycin (1 mg/ml) for 5h in presence of Brefeldin A
(10 mg/ml) for the last 4 hours in Texmacs medium (Miltenyi Biotec). In order to select viable cells, Fixable Viability Dye eF506
(ThermoFisher Scientific) was used as viability marker. Fc receptors were blocked before staining (BD Biosciences) and cells
were permeabilized with Fix/Perm kit (Ebiociences) for intracellular staining. Cell phenotype was analyzed by flow cytometry using
the LSR II (BD Biosciences, Mountain View, CA) and Flowjo software (Tree Star. Inc. USA, version 10).
Tetramer staining
Tetramerizations of RT1.Aa/Du51, RT1.Aa/Bu31-10 and control RT1.Aa/MTF-E (ILFPSSERLISNR) were performed using either strep-
tavidin-PE (Jackson ImmunoResearch) or streptavidin-APC (BD Biosciences) for the first two and streptavidin-BV421 (Biolegend) for
the later as previously described (Picarda et al., 2014). Briefly, streptavidin was added at a 4:1-molar monomer:streptavidin ratio, in
four equal aliquots added at 15-min intervals at room temperature.
For staining, three tetramers were mixed and added at 10 mg/mL to cells for 1 hour at 4C. Cells were then stained for CD8 (clone
OX8, PECy7) and CD45RC (clone OX22, A488). Cells were then fixed, permeabilized and stained for Foxp3 (Clone FJK-16 s, Pacific
Blue) using the BD cytofix/cytoperm kit (BD Biosciences) according to the manufacturer’s instructions. Fluorescence was analyzed
on a FACS Canto II cytometer (BD Biosciences) after excluding dead cells and non-specific staining.
Cytokine assays
IFNg and IL-10 were measured in coculture supernatants using ELISA kits from BD Biosciences OptEIA. IL-12 and TGFb were
measured in coculture supernatants using ELISA kit from Invitrogen and R&D System respectively.
Peptide therapy in vivo
16-mer Bu31 peptide was dissolved in 0.4%DMSO/PBS and used in mini osmotic pumps (ALZET) implanted intraperitoneally (i.p) in
recipients that delivered continuously 0.5 or 1mg/day for 14 days starting on day7 before transplantation and replaced at day +7 for
another 2 weeks. LEW.1A or third part BN allografts were monitored daily by palpation and allograft rejection was defined as com-
plete cessation of palpable heartbeat. Depleting anti-CD8amAb (OX8 clone, IgG1) was injected i.p. twice a week at a dose of 3mg/kg
starting 7 days before transplantation and until rejection.
Adoptive cell transfer
150x106 total splenocytes from naive or Bu31-treated tolerant LEW.1A recipients or 2,5x106 sorted CD8+CD45RClow Tregs from the
spleen of Bu31-treated tolerant LEW.1A recipients were transferred by i.v. injection into sublethally irradiated (4.5 Gy whole-body
irradiation) LEW.1A recipients one day before transplantation.
Expansion in vitro of human CD8+CD45RClow Tregs
5x105 CD8+CD45RClow Tregs and 2x106 autologous APCs from HLA-A2+ healthy donors were seeded in a 24 well plate in Texmacs
Medium (Miltenyi Biotec), supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), rhIL-2 (1000 U/ml, Proleukin, Novartis),
rhIL-15 (10ng/ml, Miltenyi Biotec), CpG (0.5 mM), and the different peptides (120 mg/ml) derived from HLA-II molecule (GenScript). As
negative control, a negative irrelevant peptide (ALIAPVHAV) was used. As a positive control, CD8+CD45RClow Tregs were stimulatede5 Cell Reports 29, 4245–4255.e1–e6, December 24, 2019
with plate-coated anti-CD3 (clone: OKT3, 1 mg/ml) mAb and soluble anti-CD28 mAb (clone: CD28.2; 1 mg/ml). At day 7, Tregs were
counted and re-expanded. Cytokines were freshly added twice a week. Finally, at day 14, cells were used for experiments.
Protein purification and structure determination
Heavy chain of RT1.Aa (1–275) and rat b2 m were cloned into pET30 vector for expression in BL21 Escherichia coli cells as inclusion
bodies. Inclusion bodies were then extracted using several wash buffers, and solubilized in 6 M guanidine. Solubilized inclusion
bodies containing RT1.Aa and b2 m, respectively, were used to refold pMHC complexes using the three peptides: Bu31-10 peptide
(YLRYDSDVGEYR), Du51 peptide (NREEYARFDSDVGEYR), and Bu31 peptide (YLRYDSDVGEYRAVTE). Refolding was performed
in a cold solution (4C) containing: 3M urea, 10 mM Tris-HCl pH 8, 2 mM Na-EDTA, 400 mM L-arginine-HCl, 0.5 mM oxidized gluta-
thione, and 5 mM reduced glutathione. Each pMHC was then purified using a series of anion exchange chromatography columns.
Crystals of the RT1.Aa/Bu31-10 complex were grown by the vapor-diffusion method in a hanging-drop configuration at 20C, at a
concentration of 10mg/mL in 0.1MBis-Tris-Propane pH 6.6, 28%PEG8000 and 0.2MMg2SO4. Crystals were directly flash frozen in
liquid nitrogen and data were collected on the MX2 beamline at the Australian Synchrotron, Clayton using the ADSC-Quantum 315r
CCD detector (at 100K). Data were processed using XDS (Kabsch, 2010), and AIMLESS software (Evans andMurshudov, 2013) from
the CCP4 suite. The structure was determined by molecular replacement using the PHASER program (Read, 2001); the RT1.Aa-
MTF-E structure without the peptide was used as the search MHC model (PDB: 1ED3; Speir et al., 2001). Manual model building
was conducted using the Coot software (Emsley et al., 2010) followed by maximum-likelihood refinement with the Buster program
(Smart et al., 2012). The final model has been validated using the Protein Data Base validation website and final refinement statistics
are summarized in Table S2. All molecular graphics representations were created using PyMol (DeLano, 2002).
Thermal stability assay
Stability of the three peptide-RT1.Aa complexes was assessed using a thermal shift assay. The fluorescent dye Sypro orange was
used to monitor the protein unfolding, using a Real Time Detection system (Corbett RotorGene 3000) originally designed for PCR.
Each pMHC complex was tested twice at two different concentrations (5 and 10 mM) in duplicate in 10 mM Tris-HCl pH8,
150mMNaCl. Each pMHCwas heated from 25 to 95C, and the fluorescence intensity measured (excitation at 530 nm, and emission
at 555 nm). The Tm, or thermal melting point, represents the temperature for which 50% of the protein is unfolded. The results are
reported in Table S1.
QUANTIFICATION AND STATISTICAL ANALYSIS
For the peptide activation test, a non-parametricWilcoxon signed-rank test, comparing columnmedian to a hypothetical value of 1.0,
was done. Statistical significance for the phenotype of activated cells, cytokine expression and proliferation assay was evaluated by
a one-tailed Mann Whitney t test. Allo-antibody titration and suppression assay with range of doses were analyzed by Two Way An-
ova Matched test and Bonferroni post-test. Graft survival was analyzed by Kaplan-Meier log-rank test. Analyses were made with
GraphPad Prism 7 software (GraphPad).
DATA AND CODE AVAILABILITY
Data Resources
Crystal structure files for the RT1.Aa/Bu31-10 crystal structure have been deposited in the PDB under accession number 6NF7.Cell Reports 29, 4245–4255.e1–e6, December 24, 2019 e6
